[1] 刘金伟, 董俊丽, 邵钰, 等. 基于FAERS的哌拉西林他唑巴坦不良事件信号挖掘与分析[J]. 中国药师, 2024, 27(7): 1231-1239.
[2] 张鸿儒, 杨莉萍. 含哌拉西林制剂不良反应的系统评价[J]. 中国循证医学杂志, 2023, 23(2): 191-196.
[3] 陈耀哲, 詹云丽, 宋兴栋, 等. 48例哌拉西林钠他唑巴坦钠血液系统不良反应分析[J]. 中国药物警戒, 2025, 22(7): 794-798. doi:  10.19803/j.1672-8629.20240988
[4] WIWANITKIT V. Extreme thrombocytosis: what are the etiologies?[J]. Clin Appl Thromb Hemost, 2006, 12(1): 85-87. doi:  10.1177/107602960601200113
[5] SPIVAK J L, SILVER R T. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal[J]. Blood, 2008, 112(2): 231-239. doi:  10.1182/blood-2007-12-128454
[6] SCHAFER A I. Thrombocytosis[J]. N Engl J Med, 2004, 350(12): 1211-1219. doi:  10.1056/NEJMra035363
[7] VO Q T, THOMPSON D F. A review and assessment of drug-induced thrombocytosis[J]. Ann Pharmacother, 2019, 53(5): 523-536. doi:  10.1177/1060028018819450
[8] 陈沈珏, 李昕, 刘丽华, 等. 药物致继发性血小板增多症文献分析[J]. 中国药师, 2017, 20(9): 1633-1635. doi:  10.3969/j.issn.1008-049X.2017.09.031
[9] JOSEFSDOTTIR K S, BALDRIDGE M T, KADMON C S, et al. Antibiotics impair murine hematopoiesis by depleting the intestinal microbiota[J]. Blood, 2017, 129(6): 729-739. doi:  10.1182/blood-2016-03-708594
[10] CAZZOLA M. Molecular basis of thrombocytosis[J]. Haematologica, 2008, 93(5): 646-648. doi:  10.3324/haematol.13194
[11] DAME C, SUTOR A H. Primary and secondary thrombocytosis in childhood[J]. Br J Haematol, 2005, 129(2): 165-177. doi:  10.1111/j.1365-2141.2004.05329.x
[12] 中华医学会血液学分会白血病淋巴瘤学组. 原发性血小板增多症诊断与治疗中国专家共识(2016年版)[J]. 中华血液学杂志, 2016, 37(10): 833-836.
[13] 张娟, 王颖琳, 赵泉. 哌拉西林钠他唑巴坦钠致血小板增多症[J]. 药物不良反应杂志, 2022, 24(3): 157-159. doi:  10.3760/cma.j.cn114015-20210518-00585
[14] 曾建涛, 李泉. 哌拉西林钠他唑巴坦钠相关血小板增多[J]. 药物不良反应杂志, 2016, 18(2): 142-143.
[15] 戚蕾. 哌拉西林钠他唑巴坦钠致继发性血小板增多1例[J]. 中国临床药学杂志, 2021, 30(6): 462-465.
[16] FINSTERER J, KOTZAILIAS N. Thrombocytosis under ciprofloxacin and tazobactam/piperacillin[J]. Platelets, 2003, 14(5): 329-331. doi:  10.1080/09537100310001594543
[17] 于雅卉, 沈江华, 褚燕琦. 哌拉西林钠/舒巴坦钠致继发性血小板增多症伴迟发型皮疹1例[J]. 中国药物应用与监测, 2019, 16(6): 383-385. doi:  10.3969/j.issn.1672-8157.2019.06.017
[18] 孙为为, 艾常虹. 哌拉西林钠他唑巴坦钠引起继发性血小板增多症两例[J]. 中国处方药, 2025, 23(13): 103-108. doi:  10.3969/j.issn.1671-945X.2025.13.025
[19] 赵小英. 抗微生物药物血液系统不良反应[C]. 2012年浙江省内科学年会论文集, 2012 : 6.
[20] HAN H, YAN H, KING K Y. Broad-spectrum antibiotics deplete bone marrow regulatory T cells[J]. Cells, 2021, 10(2): 277. doi:  10.3390/cells10020277
[21] BUSS D H, CASHELL A W, O’CONNOR M L, et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases[J]. Am J Med, 1994, 96(3): 247-253. doi:  10.1016/0002-9343(94)90150-3
[22] ALBERIO L. Do we need antiplatelet therapy in thrombocytosis? Pro. Diagnostic and pathophysiologic considerations for a treatment choice[J]. Hamostaseologie, 2016, 36(4): 227-240. doi:  10.5482/HAMO-14-11-0074
[23] HARRISON C N, BAREFORD D, BUTT N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis[J]. Br J Haematol, 2010, 149(3): 352-375. doi:  10.1111/j.1365-2141.2010.08122.x